Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, Muscle-Invasive Bladder Cancer
NCT02885974Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2016
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of celecoxib oral solution in bladder cancer, sponsored by Baylor College of Medicine. Primary endpoints: mRNA expression in pre- and post-chemotherapy tissues and Number and severity of adverse events. Started Dec 2016; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02885974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885974.